top of page
Browse by category
Search
Fractyl gains US$100 million financing to expand clinical development programs for T2DM
Fractyl Health (formerly Fractyl Laboratories) has closed a US$100 million Series F financing to support multiple late-stage clinical...
Revita DMR granted FDA Breakthrough Device Designation for T2DM
Fractyl Laboratories has announced that the FDA has granted Breakthrough Device Designation for Revita DMR (duodenal mucosal resurfacing)...
INSPIRE: Revita DMR plus GLP-1RA shows durable insulin-free glycaemic control
Outcomes form the investigator-initiated INSPIRE clinical trial, conducted in collaboration with Fractyl, have demonstrate that a...
Browse by tag
bottom of page